When BCMA-directed therapy is not an option, how should we treat late relapse?

During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Xavier Leleu, Poitiers University Hospital, Poitiers, FR. We asked, When BCMA-directed therapy is not an option, how should we treat late relapse?

Leleu discusses three alternatives to anti-B-cell maturation antigen (BCMA) directed therapies, including alternative drugs (provided the patient is nonrefractory), enrolment to clinical trials investigating new treatments, and the use of developing agents administered in the context of compassionate use.

Hosted on Acast. See acast.com/privacy for more information.